An interventional study of Best Practice Advisory Computerized Alert in Primary Aldosteronism, Resistant Hypertension and Secondary Hypertension, sponsored by Brigham and Women's Hospital. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.
Sponsored by Brigham and Women's Hospital · Not applicable, Interventional, and Screening
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Hyperaldosteronism with a site in United States — 4 open to participants now, 7 under way, 1 of them phase 3. Hyperaldosteronism · United States.
Among the 19 studies in Hyperaldosteronism with a site in United States, this one is one of 2 that started in 2024, is one of 2 with no phase, and was the 17th registered.
201 studies on the registry are indexed under Hyperaldosteronism; 91 are open to participants now.
Browse Hyperaldosteronism studies →4 of the 19 studies in Hyperaldosteronism with a site in United States are open now. Recruiting first, the newest first:
National Cancer Institute (NCI) · Sites in United States
Ages 18–120
Brigham and Women's Hospital · Sites in United States
Ages 18–85
Duke University · Sites in United States, Canada
Ages 0–20 · Healthy volunteers
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Sites in United States
Ages 7–70 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 68 Hyperaldosteronism studies recruiting now, 22 (32%) set no upper age limit and 30 (44%) stop at 75 or younger; 6 take children under 18; 14 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 1981; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 12,501 is above the median of 63 across 94 interventional studies indexed under Hyperaldosteronism.
Median enrollment 41 across the 9 interventional studies, 514 across the 9 observational. Of the 12 that completed or were terminated, 4 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 19 have an industry lead sponsor. The 10 most frequent:
Brigham and Women's Hospital is the lead sponsor of 1,270 studies on the registry; 230 are open to participants now.
Of its 117 completed or terminated interventional studies of FDA-regulated products, 65 (56%) have results posted.
Brigham and Women's Hospital has 5 studies filed under Hyperaldosteronism — fewer than ten, so there is no comparison to draw.
4 of the studies in Hyperaldosteronism with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07007793Phase 3AstraZenecaParent Study: A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary Aldosteronism Sub-study: A Follow-up Substudy After Completion of the BaxPA Main Study. | 2027-07-27 |
| NCT04278404Duke UniversityPharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) | 2026-11 |
| NCT03374215National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Clinical and Molecular Characteristics of Primary Aldosteronism in Blacks | 2026-12-31 |
| NCT05030545Brigham and Women's HospitalCardiovascular Manifestations of MR Activation in Primary Aldosteronism: Pilot Clinical Study | 2027-10-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 19 studies in Hyperaldosteronism with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Primary aldosteronism (PA) is common but rarely recognized cause of hypertension that carries excess cardiovascular and renal risk and has approved targeted treatments. Despite current clinical guidelines that recommend screening in a defined set of high-risk populations, less than 5% of eligible patients are ever screened for PA. This study aims to evaluate the impact of a computer decision support Best Practice Advisory (BPA) alert on rates of screening for PA in guideline-eligible patients, referral to specialist PA care, and treatment with mineralocorticoid receptor antagonists.
The study protocol is a single-center Quality Improvement initiative performed as a cluster-randomized controlled trial designed to evaluate the impact of an EPIC electronic health record Best Practice Advisory (BPA) alert on rates of screening for PA in guideline-eligible patients. All patients meeting inclusion/exclusion criteria for Primary Aldosteronism (PA) screening seen over the 12-week enrollment period will comprise the study population, with randomization of alert/no alert occurring at the level of their treating clinician (Attending Physician, Nurse Practitioner, or Physician Assistant) to minimize spillover/contamination effects of the BPA onto other patients treated by the same clinician. Treating clinicians within primary care and relevant specialties including endocrinology, nephrology, and cardiology will be randomized 1:1 to receive or not receive a BPA prompting screening for PA with laboratory testing of plasma aldosterone, plasma renin activity, and a basic metabolic panel, as well as an order for an e-consult to provide guidance on interpretation of results, for eligible patients. Outcomes will be ascertained by electronic health record review at 6 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
History of Hypertension (ICD Code) PLUS ≥1 of the below:
Exclusion Criteria:
An on-screen electronic alert will be issued during the outpatient clinical encounter that notifies the clinician that their patient should be screened for Primary Aldosteronism and provides an order set for the corresponding laboratory evaluation. Details of the electronic alert are provided in the Intervention description.
Other: Best Practice Advisory Computerized Alert
No electronic alert will be issued in the No Intervention group. Providers will continue standard of care with their patients.
For patients randomly assigned to the BPA Alert Group, an on-screen electronic alert will be issued during the outpatient clinical encounter than notifies the clinician that their patient should be screened for PA. The clinician will be provided with on-screen details of which patient-specific risk factors qualified them for PA screening and with an option to order a plasma renin activity, aldosterone, and basic metabolic panel. If screening labs are ordered, the clinician will also receive an option to order an eConsult for expert guidance on interpretation of the test results. If the clinician does not order the PA screening labs, they will be able to continue with clinical EHR documentation but will need to select a reason they opted not to follow the alert's evidence-based clinical practice recommendation.
Frequency of PA Testing Orders by Provider
The primary outcome is the frequency of aldosterone/renin laboratory testing orders placed by providers.
Time frame: 6 months
Frequency of PA-related Specialty Referral
Frequency of referral to specialist who may treat PA (endocrinology, cardiology, or nephrology)
Time frame: 6 months
Frequency of Empiric Mineralocorticoid Receptor Antagonist (MRA) Prescription
Frequency of prescription of empiric MRA such as spironolactone, eplerenone, or finerenone
Time frame: 6 months
Frequency of New PA-related Diagnoses
Frequency of new ICD Diagnostic Code for PA, Secondary Hypertension, or Endocrine Hypertension
Time frame: 6 months
Frequency of E-Consult Order by Provider
Frequency of provider ordering an E-Consult with a PA-specialist
Time frame: 6 months
Frequency of "Positive" PA Results
Frequency of a suppressed plasma renin activity \<=1 and aldosterone \>=7.5 among patients who are screened.
Time frame: 6 months
All patients meeting study eligibility were identified by an automated best practice advisory (BPA) system within the Epic electronic medical record and randomized at the clinician level based on provider NPI during the 12-week enrollment period. Inclusion criteria were primary aldosteronism screening indications and a clinical practitioner in primary care, cardiology, nephrology, or endocrinology. This resulted in a study population of 12501 patients randomized to an active BPA or no alert.
| Milestone | BPA Alert Intervention - Patients | No Alert Intervention - Patients |
|---|---|---|
| Started | 6109 | 6392 |
| Completed | 6109 | 6392 |
| Not completed | 0 | 0 |
The primary outcome is the frequency of aldosterone/renin laboratory testing orders placed by providers.
| Participants | BPA Alert Intervention - Patients | No Alert Intervention - Patients |
|---|---|---|
| Frequency of PA Testing Orders by Provider | 401 | 98 |
Frequency of referral to specialist who may treat PA (endocrinology, cardiology, or nephrology)
| Participants | BPA Alert Intervention - Patients | No Alert Intervention - Patients |
|---|---|---|
| Frequency of PA-related Specialty Referral | 733 | 746 |
Frequency of prescription of empiric MRA such as spironolactone, eplerenone, or finerenone
| Participants | BPA Alert Intervention - Patients | No Alert Intervention - Patients |
|---|---|---|
| Frequency of Empiric Mineralocorticoid Receptor Antagonist (MRA) Prescription | 143 | 173 |
Frequency of new ICD Diagnostic Code for PA, Secondary Hypertension, or Endocrine Hypertension
| Participants | BPA Alert Intervention - Patients | No Alert Intervention - Patients |
|---|---|---|
| Frequency of New PA-related Diagnoses | 13 | 12 |
Frequency of provider ordering an E-Consult with a PA-specialist
| Participants | BPA Alert Intervention - Patients | No Alert Intervention - Patients |
|---|---|---|
| Frequency of E-Consult Order by Provider | 20 | 0 |
Frequency of a suppressed plasma renin activity \<=1 and aldosterone \>=7.5 among patients who are screened.
| Participants | BPA Alert Intervention - Patients | No Alert Intervention - Patients |
|---|---|---|
| Frequency of "Positive" PA Results | 40 | 22 |
Collected over N/A - Adverse events were not assessed.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| BPA Alert Intervention - Patients | — | — | — |
| No Alert Intervention - Patients | — | — | — |
| Age, Continuous(years) | BPA Alert Intervention - Patients | No Alert Intervention - Patients | Total |
|---|---|---|---|
| Mean | 69.7 ± 12.9 | 71.1 ± 12.9 | 70.4 ± 12.9 |
| Sex: Female, Male(Participants) | BPA Alert Intervention - Patients | No Alert Intervention - Patients | Total |
|---|---|---|---|
| Female | 3475 | 3394 | 6869 |
| Male | 2634 | 2998 | 5632 |
| Race (NIH/OMB)(Participants) | BPA Alert Intervention - Patients | No Alert Intervention - Patients | Total |
|---|---|---|---|
| American Indian or Alaska Native | 8 | 11 | 19 |
| Asian | 167 | 161 | 328 |
| Native Hawaiian or Other Pacific Islander | 2 | 5 | 7 |
| Black or African American | 806 | 738 | 1544 |
| White | 4448 | 4807 | 9255 |
| More than one race | 50 | 46 | 96 |
| Unknown or Not Reported | 628 | 624 | 1252 |
| Ethnicity (NIH/OMB)(Participants) | BPA Alert Intervention - Patients | No Alert Intervention - Patients | Total |
|---|---|---|---|
| Hispanic or Latino | 570 | 607 | 1177 |
| Not Hispanic or Latino | 5101 | 5280 | 10381 |
| Unknown or Not Reported | 438 | 505 | 943 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Mar 2024 to primary completion in Dec 2024, 8 months.
Results were first posted in Nov 2026, 1 year 10 months after primary completion.
Of 36 interventional studies with no phase under Hyperaldosteronism, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's 8 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Brigham and Women's Hospital →